Cryo-Cell International Net Income Drops 83% to $47,100 in Q1 FY2026
Cryo-Cell International, a cord blood and tissue cryopreservation company, posted net income of $47,100 for the three months ending February 28, 2026, down sharply from $282,855 in the prior-year quarter. Operating income declined 28% amid higher selling, general and administrative expenses.
Cryo-Cell International, Inc., a cord blood and tissue cryopreservation company, reported net income of $47,100 for the three months ending February 28, 2026, an 83% decline from $282,855 in the same period a year earlier. The company's operating income fell to $765,134 from $1.06 million in the prior-year quarter. Read more earnings reports.
The profit decline came as selling, general and administrative expenses climbed to $5.01 million from $4.64 million year-over-year. Cost of goods sold dropped to $1.66 million from $1.98 million, while research and development expenses declined to $65,761 from $98,143.
Interest expense decreased to $462,709 from $494,962 in the year-ago period. The company recorded income tax expense of $23,201 compared with $250,863 a year earlier. Earnings per share came in at $0.01 on both a basic and diluted basis, down from $0.03 per share in the prior-year quarter.
Cryo-Cell generated $651,827 in cash from operations for the quarter, down from $954,063 a year earlier. Cash from investing activities totaled $19,104, compared with a use of $287,484 in the prior period. The company used $740,290 for financing activities, versus $1.00 million a year ago.
Balance Sheet and Liquidity
Total assets stood at $60.88 million as of February 28, 2026, down from $61.73 million three months earlier. Current assets declined to $11.08 million from $11.76 million at November 30, 2025. Cash and cash equivalents totaled $249,672 compared with $319,031 at the prior quarter end.
Accounts receivable edged down to $6.82 million from $6.85 million. Inventory fell to $356,991 from $408,794. Property, plant and equipment decreased to $20.87 million from $21.03 million.
Total liabilities stood at $79.29 million, down from $80.33 million three months prior. Current liabilities declined to $17.76 million from $19.79 million. The company carried $8.32 million in long-term debt as of February 28, 2026, compared with $8.35 million at November 30, 2025.
Stockholders' deficit narrowed to $18.40 million from $18.61 million at the prior quarter end. Retained deficit improved to $38.39 million from $38.44 million. Common shares outstanding remained flat at 8.06 million.
Key Financial Metrics
| Metric | Q1 FY2026 | Q1 FY2025 |
|---|---|---|
| Net Income | $47,100 | $282,855 |
| Operating Income | $765,134 | $1,056,011 |
| Cost of Goods Sold | $1,656,488 | $1,984,588 |
| SG&A Expenses | $5,011,847 | $4,638,285 |
| Interest Expense | $462,709 | $494,962 |
| EPS (Diluted) | $0.01 | $0.03 |
| Cash from Operations | $651,827 | $954,063 |
The company recorded depreciation and amortization of $183,887 for the quarter compared with $191,853 in the year-ago period. Total assets of $60.88 million are offset by total liabilities of $79.29 million, resulting in negative stockholders' equity.